ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Currently, the second-generation c-Abl inhibitors Nilotinib and Bafetinib, clinically used in the treatment of chronic myeloid leukemia (CML), have been reported to reduce the accumulation of α-synuclein and reverse the degeneration of nigral dopaminergic neurons in PD animal models128–131.